Exelixis | EXEL - Selling And Administration Expenses


Exelixis reported $103.13M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Amgen USD 1.7B 9M Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Bayer EUR 3.4B 140M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Eisai JPY 103.86B 3.7B Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Exelixis USD 103.13M 9.8M Sep/2025
Genmab DKK 144M 18M Jun/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
MacroGenics USD 9.9M 600K Sep/2025
Merck USD 2.63B 0 Sep/2025
Moderna USD 268M 38M Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Xencor USD 87.78M 72.66M Sep/2025